• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • The Hatter Cardiovascular Institute Horizon Meetings
    • The 19th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2022 – London
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2022
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2022
    • Multiple Sclerosis Nurses at the Limits 2022
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor Richard A. Flavell

Dr. Flavell is founding chair of the Department of Immunobiology at Yale and an Investigator of the Howard Hughes Medical Institute. After obtaining a Ph.D. degree in biochemistry from the University of Hull in 1970, he carried out postdoctoral training at the University of Amsterdam and the University of Zurich.

Working with Charles Weissmann in Zurich in 1974, he modified genes in a virus and studied the resulting phenotype – the first example of what scientists now call “reverse genetics.” Subsequently, as a faculty member at the University of Amsterdam, he demonstrated the presence of introns in mammalian genes. In 1982, Dr. Flavell left academics to serve as the chief scientific officer of Biogen, but returned to academia in 1988 to join the faculty at the Yale School of Medicine.

Dr. Flavell’s research uses mouse genetics to study innate and adaptive immunity, T cell tolerance, apoptosis and autoimmunity, and the regulation of T cell differentiation. Among his most recent discoveries is the finding that genes interact across chromosomes in T cells, where a master control gene on chromosome 11 may physically touch a gene on chromosome 10, inducing it to produce a protein that primes the cell to fight infection in a specific way. This finding has wide-ranging implications for diseases including autoimmune disorders and cancer. Most recently, he has established the connection between inflammasomes, microbial homeostasis and chronic diseases. He showed that dysbiosis of the microbiota leads to IBD and Metabolic Syndrome, including Obesity, Fatty Liver disease and Type 2 diabetes.

Dr. Flavell has received the FEBS Anniversary Prize (1980), Colworth Medal (1980), Darwin Trust Prize (1995), Rabbi Shai Sachnai Memorial Prize in Immunology and Cancer Research (2008), AAI Invitrogen Meritorious Career Award (2008), Andrew Lazarovitz Award (2011), the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (2012) and most recently, the 2013 Vilcek Award, shared with Dr. Ruslan Medzhitov. He was elected to the Royal Society in 1984, the National Academy of Sciences in 2002, the Institute of Medicine in 2006 and the first President of the newly formed International Cytokine and Interferon Society (ICIS) from 2014.

« Dr. Jasmin Fisher
Dr. Roy S. Herbst »

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Cell Therapy at the Limits 2022
Monday, 27 & Tuesday, 28 June 2022, London, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Monday, 19 & Tuesday, 20 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Cardiology, Diabetes & Nephrology at the Limits Brazil
April & October 2022, Brazil

The Hatter Cardiovascular Institute Horizon GP Meeting
Wednesday, 9 November 2022
London, UK

The Hatter Cardiovascular Institute Horizon Meeting
Wednesday, 23 November 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2023
London,UK

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2022 At the Limits Ltd.
This site uses cookies More info